Therefore, SGLT2 inhibitors are important in T2DM patients with established cardiovascular disease or very high cardiovascular risk [12]. While adverse events in general were mild and rare, the study design may have truncated complete documentation in a retrospective investigation. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.